Sorrento Therapeutics Stock Price - SRNE

0.12 (4.72%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Sorrento Therapeutics Inc SRNE NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.11 -4.15% 2.54 2.51 2.69 2.69 2.65 00:00:00
Bid Price Ask Price Spread Spread % News
2.53 2.64 0.11 4.17% 2 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
10,438 3,844,550 $ 2.60 $ 9,996,562 5,771,348 1.39 - 6.50
Last Trade Time Type Quantity Stock Price Currency
19:59:49 formt 100 $ 2.66 USD

Sorrento Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 453.87M 178.69M $ -203.54M -1.91 - 74.22M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Sorrento Therapeutics News

Loading Messages....

Latest SRNE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SRNE Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.812.87992.512.663,131,549-0.27-9.61%
1 Month4.214.582.513.284,236,381-1.67-39.67%
3 Months2.855.922.513.776,010,230-0.31-10.88%
6 Months2.285.921.393.314,211,8530.2611.4%
1 Year2.236.501.393.463,075,5970.3113.9%
3 Years5.5510.651.394.202,123,837-3.01-54.23%
5 Years12.1826.801.394.881,420,140-9.64-79.15%

Sorrento Therapeutics Description

Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.